BRIEF—Pharmacosmos and Kedrion announce Monoferric deal for Italy

The Pharmacosmos Group, a Danish producer of IV iron for medical use, and Kedrion Biopharma, an Italy-based specialist in the production and distribution of plasma-derived medicinal products, have announced a collaboration.

They have entered into an exclusive agreement to distribute a novel iron-based therapy in Italy for patients suffering from iron deficiency anemia.

Under the agreement, Kedrion will exclusively distribute Monoferric, an iron-based preparation for intravenous administration produced by Pharmacosmos.

It is estimated that 5% of the female population in Italy is affected by iron deficiency anemia.

Paolo Marcucci, executive chairman of Kedrion, said: "This agreement will allow us to expand our commitment beyond that of rare diseases, redefining and consolidating our efforts to support a new community of patients affected by a disease that is very common among the population on a global scale.”